Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man
- PMID: 2328298
- DOI: 10.1002/bdd.2510110205
Dose dependent pharmacokinetics of N-acetylcysteine after oral dosing to man
Abstract
The pharmacokinetics after oral administration of 200, 600 or 1200 mg of N-acetylcysteine (NAC) were studied in 10 healthy subjects. Normalized maximal plasma concentration was significantly higher after a 600 mg dose than after a 200 mg dose. Bioavailability of NAC significantly increased with increasing dose. Time for maximal plasma concentration also increased with increasing dose. The observations can be explained by a capacity-limited presystemic elimination of NAC. In an extension of the study, 600 mg of NAC was given twice a day for 5 days and the plasma concentrations were followed after the morning dose on day 6. No differences in the pharmacokinetic parameters were observed in comparison with the single 600 mg dose. This indicates that the beneficial clinical effects observed after repeated dosing can not be ascribed to an accumulation of NAC in plasma.
Similar articles
-
Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers.Arzneimittelforschung. 1989 Mar;39(3):382-6. Arzneimittelforschung. 1989. PMID: 2757663
-
Bioavailability of suckable tablets of oral N-acetylcysteine in man.Eur J Clin Pharmacol. 1989;37(4):419-21. doi: 10.1007/BF00558514. Eur J Clin Pharmacol. 1989. PMID: 2598977
-
Phase I study of the pharmacokinetics and safety of single and multiple doses of intravenous N-acetylcysteine in healthy Chinese subjects.Eur Rev Med Pharmacol Sci. 2023 Dec;27(24):12103-12111. doi: 10.26355/eurrev_202312_34808. Eur Rev Med Pharmacol Sci. 2023. PMID: 38164872 Clinical Trial.
-
Assessment of the clinical use of intravenous and oral N-acetylcysteine in the treatment of acute acetaminophen poisoning in children: a retrospective review.Clin Ther. 2011 Sep;33(9):1322-30. doi: 10.1016/j.clinthera.2011.08.005. Epub 2011 Sep 3. Clin Ther. 2011. PMID: 21890206 Review.
-
Activated charcoal and acetylcysteine absorption: issues in interpreting pharmacokinetic data.DICP. 1991 Oct;25(10):1081-4. doi: 10.1177/106002809102501012. DICP. 1991. PMID: 1803797 Review.
Cited by
-
Acute supplementation of N-acetylcysteine does not affect muscle blood flow and oxygenation characteristics during handgrip exercise.Physiol Rep. 2016 Apr;4(7):e12748. doi: 10.14814/phy2.12748. Physiol Rep. 2016. PMID: 27044854 Free PMC article. Clinical Trial.
-
N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data.Support Care Cancer. 2006 May;14(5):484-7. doi: 10.1007/s00520-006-0018-9. Epub 2006 Feb 1. Support Care Cancer. 2006. PMID: 16450089 Clinical Trial.
-
Comparative in vitro analysis of inhibition of rhinovirus and influenza virus replication by mucoactive secretolytic agents and plant extracts.BMC Complement Med Ther. 2020 Dec 23;20(1):380. doi: 10.1186/s12906-020-03173-2. BMC Complement Med Ther. 2020. PMID: 33357221 Free PMC article.
-
Transdermal patches loaded with L-cysteine HCL as a strategy for protection from mobile phone emitting electromagnetic radiation hazards.Saudi Pharm J. 2019 Jan;27(1):112-125. doi: 10.1016/j.jsps.2018.09.004. Epub 2018 Sep 5. Saudi Pharm J. 2019. PMID: 30662314 Free PMC article.
-
Use of Thiols in the Treatment of COVID-19: Current Evidence.Lung. 2021 Aug;199(4):335-343. doi: 10.1007/s00408-021-00465-3. Epub 2021 Aug 27. Lung. 2021. PMID: 34448938 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources